In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Strategia Therapeutics Inc.

strategiatx.com

Latest From Strategia Therapeutics Inc.

Biopharma Quarterly Dealmaking Statistics, Q1 2016

Q1 biopharma financing totaled $5.7 billion, a sharp drop from Q4, but this time early-stage venture rounds were the most popular fundraising vehicle;Q1 M&A also declined, totaling $12.3 billion, mostly from Mylan's $9.9 billion buy of Meda. The top alliance was again by Sanofi, in a five-year potential $2.26 billion collaboration with DiCE Molecules to develop oral small-molecule therapies against up to 12 targets.

BioPharmaceutical Deals

Deals Shaping The Medical Industry, March 2016

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in February 2016.

BioPharmaceutical Medical Device

Deals Shaping the Medical Industry, February 2016

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in February 2016.

BioPharmaceutical Medical Device

Deals Shaping The Medical Industry, September 2014

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced June-August 2014.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
  • Contract Research, Toxicology Testing-CRO
  • Pharmaceuticals
  • Services
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Boston Strategics Corp.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Strategia Therapeutics Inc.
  • Senior Management
  • Keizo Koya, PhD, CEO, President & Founder
    Thomas J Myers, MD, CMO
    Linda Paradiso, MBA, COO
    David S Wages, MD, PhD, Medical Director
    Mary Johansen, PharmD, Dir, Reg Affairs
    Michele Rosner, MS, Dir, Clinical Ops
    Teletha Gipson, PhD, Dir, Clinical ops
    Barbara Smith, Dir, QA
  • Contact Info
  • Strategia Therapeutics Inc.
    Phone: (781) 761-0123
    214 Union Wharf
    Boston, MA 02109
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register